Clinical trial NCT04962919: Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
Official title: Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Prostatic Neoplasms, Castration-Resistant
Keywords: Prostatic Neoplasms
Lead sponsor: Latin American Cooperative Oncology Group
Sponsor class: OTHER
First posted: 2021-07-15
Enrollment: 584
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Brief summary: Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions


Eligibility criteria: Inclusion Criteria:

* Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Exclusion Criteria:

* Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;
* Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Primary outcomes:
measure: Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.
timeFrame: December of 2017
Secondary outcomes:
measure: To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;
timeFrame: December of 2017
measure: To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;
timeFrame: December of 2017
measure: To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;
timeFrame: December of 2017
measure: To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;
timeFrame: December of 2017
measure: To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;
timeFrame: December of 2017
measure: To describe the rates of skeletal-related complications
timeFrame: December of 2017
measure: To describe the rate of admissions
timeFrame: December of 2017
measure: To describe the number of lines of treatment that patients have undergone
timeFrame: December of 2017
measure: To describe the presence or absence of treatments bone-directed
timeFrame: December of 2017
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: CPO Pucrs
state: RS
city: São Paulo
country: Brazil
facility: Sírio Libanês
state: SP
city: São Paulo
country: Brazil
facility: Centro Paulista de Oncologia
state: SP
city: Santo André
country: Brazil
facility: Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO
state: São Paulo
city: São Paulo
country: Brazil
facility: Hospital Santa Marcelina
city: São Paulo
country: Brazil
facility: BP - A Beneficência Portuguesa de São Paulo
city: São Paulo
country: Brazil
facility: Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central
city: São Paulo
country: Brazil
facility: A.C.Camargo Cancer Center
Study officials:
affiliation: Latin American Cooperative Oncology Group
name: Fernando Cotait Maluf
role: PRINCIPAL_INVESTIGATOR
References: